Agilent Technologies, Inc. (A): BCG Matrix [June-2026 Updated]

This ready-made Agilent Technologies, Inc. Business analysis gives you a clear, research-based view of which parts of the portfolio are growing, which are generating cash, and which need capital discipline. It covers LC instruments, oncology diagnostics, PFAS testing, digital lab workflows, recurring consumables and service contracts, and weaker legacy areas such as CRISPR IP and China softness, using figures like $6.95B FY2025 revenue, 10.0% Q2 2026 growth, 26.4% operating margin, 15.0%-18.0% market share, and major moves including the $950.0M Biocare deal, the $925.0M BioVectra purchase, and the June 2026 AI collaboration.

Agilent Technologies, Inc. - BCG Matrix Analysis: Stars

Agilent Technologies, Inc. has several Star businesses because they combine high growth with strong market positions and healthy margins. The clearest Star areas are liquid chromatography instruments, oncology diagnostics, PFAS-related environmental testing, digital lab software, and Asia-Pacific localization.

LC instruments accelerate because Agilent launched the Infinity III LC and Pro iQ LC/MS systems on June 3, 2026, and management said they are driving double-digit growth in the LC segment. Q2 2026 revenue reached $1.83B, up 10.0% year over year, with core growth of 6.3%. The company also posted a 26.4% operating margin in Q2 2026 and is guiding FY2026 revenue to $7.39B-$7.49B. FY2025 gross margin was 52.4%, and global analytical instrumentation share was estimated at 15.0%-18.0%. This fits a Star because the platform has visible growth, premium margins, and constant product refresh.

Oncology diagnostics expands because Agilent expanded the use of PD-L1 IHC 22C3 pharmDx for esophageal and gastric cancers on Dako Omnis on June 2, 2026. The March 9, 2026 agreement to acquire Biocare Medical for $950.0M adds immunohistochemistry breadth and supports a faster push into clinical diagnostics. LDG was formally reorganized on November 25, 2024, and Simon May was named its president, showing management focus on the growth platform. FY2025 revenue was $6.95B, up 7.0%, while Q1 2026 revenue was $1.80B, up 7.0% reported and 4.4% core. That mix supports a Star because the franchise is being expanded in oncology, funded by major capital, and tied to a growing regulated market.

PFAS demand lifts Agilent because the EU Drinking Water Directive made PFAS monitoring mandatory on January 1, 2026, directly increasing demand for analytical instruments. Agilent also cited strong growth in environmental testing and pharma QA/QC, two areas that benefit from this regulation. Europe and Asia-Pacific represented 30.0% and 35.0% of FY2025 revenue, so the demand shock is landing in large addressable regions. The company's Q2 2026 revenue grew 10.0% year over year, and its operating margin expanded to 26.4%, showing that this growth is profitable. With a 15.0%-18.0% global market share in analytical instrumentation, PFAS-related demand fits a Star quadrant for a high-share, high-growth use case.

Digital lab workflows scale because Agilent introduced OpenLab Sync on May 28, 2026, and earlier launched AI-driven lab optimization tools and a ProteoAnalyzer Software Security Module at SLAS2026 on February 7, 2026. On June 3, 2026, it also announced an AI collaboration with OpenAI and BCG to deploy AI across products, operations, and customer workflows. More than 55.0% of FY2025 revenue came from recurring consumables and service contracts, which improves adoption economics for digital software layers. FY2025 R&D spending was about $600.0M, or roughly 8.0%-9.0% of revenue, supporting continuous platform development. This is a Star because Agilent is layering fast-growing software and AI capabilities onto a large installed base with strong margin support.

APAC localization gains matter because Agilent plans to invest in a new innovation center in Shanghai during FY2026 to localize product development. Asia-Pacific already contributed 35.0% of FY2025 revenue, matching the Americas and exceeding Europe's 30.0% share. China revenue declined 4.0% in Q4 2025, but management said normalization signs were emerging, which makes local innovation strategically important. FY2026 guidance calls for $7.39B-$7.49B in revenue and 85.0 basis points of operating margin expansion, implying the region can contribute to a higher-growth mix. This fits a Star profile because Agilent is trying to convert a very large geography into a higher-growth, higher-return engine.

• High growth is visible in LC instruments, diagnostics, and software-led workflow tools.
• Market share is already strong in analytical instrumentation, which supports pricing power and scale.
• Margins are attractive, with Q2 2026 operating margin at 26.4% and FY2025 gross margin at 52.4%.
• Recurring revenue from consumables and service contracts supports steadier cash flow and faster software adoption.
• Regulatory demand, especially PFAS monitoring, adds a durable growth driver in large regions.

For academic work, you can use these Star businesses to show how a company protects its position in a growth market. The key logic is simple: invest where demand is rising, the company already has scale, and the margin structure can support continued R&D and product launches.

Agilent Technologies, Inc. - BCG Matrix Analysis: Cash Cows

Agilent Technologies, Inc. fits the Cash Cow category because a large share of revenue comes from recurring consumables and service work, while the installed base keeps producing profit with limited reinvestment pressure. The core business is mature, geographically broad, and highly cash generative, which makes it a dependable funding source for dividends, buybacks, and selective growth spending.

Recurring revenue is the clearest Cash Cow signal. More than 55.0% of FY2025 revenue came from consumables and service contracts, which gives the business a steady stream of sales even when new instrument demand slows. That model aligns closely with Agilent CrossLab, which remained under Angelica Riemann after the November 25, 2024 restructuring. FY2025 revenue was $6.95B and gross margin reached 52.4%, showing that the company can convert sales into cash at a healthy rate. Q1 2026 revenue of $1.80B and Q2 2026 revenue of $1.83B also show quarter-to-quarter resilience. In BCG terms, this is a Cash Cow because the business harvests stable demand without needing outsized reinvestment.

The installed base supports profit because the company has already placed products in laboratories, diagnostics settings, and industrial workflows that need ongoing support. Agilent's global market share was estimated at 15.0% to 18.0% in analytical instrumentation during FY2025, which is a mature but meaningful position. Revenue was split across the Americas at 35.0%, Europe at 30.0%, and Asia-Pacific at 35.0%, so the company is not dependent on one region. Q2 2026 operating margin reached 26.4%, up from 21.3% in FY2025, and FY2025 net income of $1.30B plus Q2 2026 GAAP net income of $339.0M show that the installed base is being monetized efficiently. For academic analysis, this is important because it links market maturity to stable profit generation.

The capital return profile also matches a Cash Cow. Agilent completed its 2023 share repurchase program by retiring 3.0M shares for $374.0M during FY2025. It also used $51.0M of a new $2.0B 2024 authorization to repurchase 381.67K shares by October 31, 2025. The quarterly dividend increased 3.0%, and total dividends paid in FY2025 were $282.0M. Even after these payouts, FY2026 guidance still leaves $1.5B to $2.0B of capital expenditure capacity for strategic bolt-on M&A. That matters because Cash Cows should generate excess cash after maintaining the business, and Agilent is doing exactly that.

Margin discipline is another reason the classification holds. FY2025 net income was $1.30B on $6.95B of revenue, and Q2 2026 diluted EPS was $1.20. The Ignite operating system delivered more than $150.0M in annualized savings as of October 31, 2025, which shows management is protecting profitability rather than chasing growth at any cost. FY2025 R&D was about $600.0M, or roughly 8.0% to 9.0% of revenue, which is a controlled reinvestment level for a mature business. Q1 2026 and Q2 2026 combined revenue of $3.63B shows the underlying run rate remains stable.

• High recurring revenue reduces reliance on one-time instrument sales.
• Strong gross margin improves cash generation after direct costs.
• Stable operating margin shows the business can hold profitability through cycles.
• Moderate R&D spending supports the base without overconsuming cash.
• Buybacks and dividends show excess cash is available after core needs are met.

Sustainability assets also strengthen the Cash Cow profile because they support retention, refurbishment, and longer asset life. Agilent had increased the share of instrument revenue from My Green Lab ACT-labeled products to 40.0% by June 27, 2024. It had also reduced Scope 1 and 2 emissions by 8.0% since 2019 and refurbished 5.4K instruments in FY2023. These actions matter because refurbishment and service tend to keep customers inside the ecosystem longer, which increases recurring revenue and lowers replacement friction. With recurring revenue above 55.0% and FY2025 gross margin at 52.4%, the sustainability platform supports an annuity-like business model that keeps generating cash from an existing product base.

For a BCG Matrix write-up, you can frame this chapter as the part of the portfolio that funds the rest of the company. The Cash Cow role is not about rapid growth; it is about dependable earnings, strong margins, and disciplined cash use. Agilent's recurring revenue mix, mature installed base, broad geographic spread, and shareholder returns all point to a business that is already past the aggressive growth stage but still highly valuable because it produces cash consistently.

Agilent Technologies, Inc. - BCG Matrix Analysis: Question Marks

Agilent Technologies, Inc. has several businesses that fit the Question Mark category because they sit in faster-growing markets, but their market share and profit payoff are not yet proven. In BCG terms, these are areas where Agilent is spending heavily to build position, but the business has not yet shown clear leadership or a completed return on capital.

The key issue is simple: Agilent is making large bets in adjacent markets, but the financial evidence is still incomplete. That matters because Question Marks can become Stars if execution is strong, or they can stay expensive if adoption stays weak.

Biocare requires scale. Agilent announced on March 9, 2026 that it would acquire Biocare Medical for $950.0M. The goal is to expand immunohistochemistry offerings, especially after the June 2, 2026 PD-L1 label expansion on Dako Omnis. This is strategically sensible because diagnostic labels can widen the addressable market, but the benefit is not yet reflected in reported results. No completed post-close market share or revenue contribution had been reported as of June 2026.

This keeps the business in Question Mark territory. Agilent is already spending about $600.0M annually on R&D and expects $1.5B-$2.0B of FY2026 capital expenditure capacity. That gives the company enough financial strength to absorb the deal, but funding capacity is not the same as proof of success. In BCG terms, the market opportunity is visible, while the return on investment is still untested.

Oligo platform still proving. Agilent invested $700.0M in an oligonucleotide manufacturing facility in Frederick, Colorado, with full operation slated for 2025. It also completed the $925.0M BioVectra acquisition on July 22, 2024, adding specialized CDMO capability. CDMO means contract development and manufacturing organization, which is a business that makes products for other firms under contract.

These moves place Agilent in a higher-growth manufacturing lane, but the financial payoff has not yet been confirmed. No June 2026 share or margin disclosure has been provided for the oligo/CDMO stack. FY2025 revenue was $6.95B, and Q2 2026 revenue grew 10.0%, so the company has the scale to fund the expansion. Even so, this remains a Question Mark because the asset base is large and strategic, yet competitive payback is still unproven.

• The Frederick plant adds capacity in a specialized market where scale can matter over time.
• The BioVectra deal broadens Agilent's manufacturing and service footprint.
• The missing piece is proof that these assets will lift margins and market share.

AI bet is early. Agilent announced on June 3, 2026 a collaboration with OpenAI and BCG to deploy AI across products, operations, and customer workflows. It had already introduced AI-driven lab optimization tools at SLAS2026 on February 7, 2026 and OpenLab Sync on May 28, 2026. These are useful because AI can reduce manual work, speed analysis, and improve customer retention.

Agilent is backing this with about $600.0M in annual R&D and an Ignite program that has already generated over $150.0M in annualized savings. That shows internal capacity to fund experimentation. Still, there is no reported June 2026 revenue contribution from the AI initiative. The growth thesis is active, but monetization is still emerging, which is the classic Question Mark profile.

Shanghai investment is uncertain. Agilent plans to open a new innovation center in Shanghai in FY2026 to localize product development. The strategic logic is clear: local development can shorten response times, improve customer fit, and reduce friction in a major market. This matters more in China, where regulatory, procurement, and technical preferences often differ from the US.

China revenue declined 4.0% in Q4 2025, even though management said normalization was beginning. Asia-Pacific accounts for 35.0% of revenue, so the region is too important to ignore. However, the company has not published a June 2026 share gain or payback metric tied to the Shanghai center. That leaves the investment unproven in financial terms.

Targeted sequencing remains niche. Agilent entered a co-marketing agreement with Wasatch BioLabs on December 19, 2025 for native-read targeted sequencing. This is the kind of move that can help Agilent test demand without taking on the full cost of a broad platform launch. It also fits a portfolio strategy: build access first, then decide whether to scale.

The challenge is that Agilent is balancing a $950.0M Biocare acquisition, a $925.0M BioVectra purchase, and $1.5B-$2.0B of FY2026 capital expenditure capacity. Those investments show intent to build new adjacencies, but no June 2026 market share or revenue breakout has been disclosed for sequencing. FY2025 market share in analytical instrumentation was 15.0%-18.0%, yet that does not prove leadership in this newer niche.

• Sequencing is attractive because it can support future growth in life sciences tools.
• The current scale is still too small to classify as a Star or Cash Cow.
• The business needs revenue visibility before it can be treated as a mature core asset.

Why these Question Marks matter strategically. They show where Agilent is trying to move from a strong core into higher-growth markets. That matters because the company's legacy businesses can fund investment, but future growth depends on whether these newer bets convert into durable share. In a BCG Matrix analysis, the core issue is not just spending; it is whether spending creates leadership.

Financial pressure and opportunity sit together. Agilent's R&D intensity and capex capacity support experimentation, but each Question Mark also absorbs capital, management attention, and integration work. If one of these bets scales, it can improve revenue growth and operating leverage. If not, it can dilute returns and keep margins under pressure. That is why these units are best treated as high-potential, unproven growth bets rather than established winners.

Agilent Technologies, Inc. - BCG Matrix Analysis: Dogs

Agilent Technologies, Inc. has a few legacy areas that fit the Dog category because they carry low growth, weak strategic pull, or heavy cost without a clear path to stronger returns. These pockets do not look like the best place for scarce capital when the company is already generating $6.95B in FY2025 revenue and spending about $600.0M on R&D.

CRISPR IP has been lost. On April 1, 2026, the U.S. Supreme Court declined to hear Agilent v. Synthego, which finalized the invalidation of two CRISPR-related patents. That matters because the company no longer has legal leverage in a technology area with no identifiable June 2026 revenue stream in the provided data. Agilent's main business comes from its $6.95B FY2025 revenue base and a 15.0%-18.0% share in analytical instrumentation. Against that backdrop, about $600.0M of R&D should prioritize areas with clearer commercial payback. This is a Dog because the patent position has weak monetization and no visible growth path.

China legacy softness remains. China revenue fell 4.0% in Q4 2025, and management only said conditions were normalizing, not that a rebound was secured. The plan to build a Shanghai innovation center in FY2026 suggests the current setup needs repair before it can produce stronger results. Tariffs and inflationary pressure on supply-chain costs were still cited on May 29, 2026, which adds another layer of strain. With Asia-Pacific contributing 35.0% of revenue, this weakness matters even when overall Q2 2026 revenue rose 10.0%. This is a Dog because the region is under pressure and lacks a confirmed growth or share advantage.

• China weakness matters more because it sits inside a region that accounts for 35.0% of revenue.
• A Shanghai innovation center may help later, but it also signals that the current structure is not enough.
• Tariff and inflation pressure can hit both sales momentum and margins at the same time.

Compliance burden is heavy. Agilent said in FY2026 that it is implementing advanced data integrity modules for 21 CFR Part 11 compliance. It also expects higher taxes in 2026 because of global tax regulations, after a favorable tax impact in 2025. These burdens sit beside tariff and supply-chain inflation pressure cited on May 29, 2026. Even with Q2 2026 operating margin at 26.4%, this compliance-heavy layer does not point to a distinct growth engine. This is a Dog because the economics are burdened by regulation and cost without a matching market-growth signal.

Legacy legal overhangs last. The 2026 closure of the CRISPR case removed a patent set that had already been weakened by litigation. Institutional ownership was about 92.5% on June 9, 2026, so the market is focused on core operating performance rather than this legacy asset. The company's strongest growth proof is elsewhere, including 10.0% Q2 2026 revenue growth and double-digit local-currency growth. No June 2026 revenue or margin contribution has been tied to the invalidated patent area. That makes the legacy legal overhang a Dog because it absorbs attention without adding operating value.

Tariff-sensitive inputs weaken economics. On May 29, 2026, management again cited tariffs and possible inflationary pressure on supply-chain costs. This matters because Agilent's FY2025 gross margin was 52.4% and its Q2 2026 operating margin was 26.4%, both of which can be squeezed by higher input costs. The company is trying to offset this through Ignite savings of more than $150.0M annually and a $1.5B-$2.0B capital plan. But no specific low-growth product line has been shown to benefit from those cost pressures. This is a Dog because the tariff-exposed cost layer is low-return and structurally unattractive relative to higher-growth businesses.

• Use the CRISPR issue as an example of a stranded asset in a BCG Matrix assignment.
• Use China softness to show how a regional Dog can matter even inside a strong company.
• Use compliance and tariff pressure to explain why low-growth areas can drain returns.